You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the LONSURF (tipiracil hydrochloride; trifluridine) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR LONSURF

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for LONSURF

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01896856 ↗	Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer	Completed	Astex Pharmaceuticals, Inc.	Phase 1/Phase 2	2013-10-23	This is a phase I/II study of the combination of Guadecitabine (SGI-110) and previously treated metastatic colorectal cancer patients. This study will be conducted in two components. First, patients will be enrolled in a phase I study of SGI-110 combined with irinotecan in a standard 3+3 design. After the maximum tolerated dose (MTD) is determined, patients will subsequently be enrolled in a 2:1 randomized phase II study of SGI-110 and irinotecan versus the standard of care regorafenib or Lonsurf (TAS-102).
NCT01896856 ↗	Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer	Completed	Van Andel Research Institute	Phase 1/Phase 2	2013-10-23	This is a phase I/II study of the combination of Guadecitabine (SGI-110) and previously treated metastatic colorectal cancer patients. This study will be conducted in two components. First, patients will be enrolled in a phase I study of SGI-110 combined with irinotecan in a standard 3+3 design. After the maximum tolerated dose (MTD) is determined, patients will subsequently be enrolled in a 2:1 randomized phase II study of SGI-110 and irinotecan versus the standard of care regorafenib or Lonsurf (TAS-102).
NCT01896856 ↗	Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 1/Phase 2	2013-10-23	This is a phase I/II study of the combination of Guadecitabine (SGI-110) and previously treated metastatic colorectal cancer patients. This study will be conducted in two components. First, patients will be enrolled in a phase I study of SGI-110 combined with irinotecan in a standard 3+3 design. After the maximum tolerated dose (MTD) is determined, patients will subsequently be enrolled in a 2:1 randomized phase II study of SGI-110 and irinotecan versus the standard of care regorafenib or Lonsurf (TAS-102).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for LONSURF

Condition Name

Chart
Table

Condition Name for LONSURF
Intervention	Trials
Stage IVC Colorectal Cancer AJCC v8	6
Metastatic Colorectal Cancer	6
Stage IV Colorectal Cancer AJCC v8	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for LONSURF
Intervention	Trials
Colorectal Neoplasms	29
Adenocarcinoma	20
Carcinoma	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for LONSURF

Trials by Country

Map
Table

Trials by Country for LONSURF
Location	Trials
United States	112
Australia	13
Japan	12
France	6
Canada	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for LONSURF
Location	Trials
California	12
Florida	11
Texas	9
Minnesota	9
Arizona	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for LONSURF

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for LONSURF
Clinical Trial Phase	Trials
Phase 3	5
Phase 2/Phase 3	1
Phase 2	30
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for LONSURF
Clinical Trial Phase	Trials
Recruiting	26
Not yet recruiting	10
Active, not recruiting	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LONSURF

Sponsor Name

Chart
Table

Sponsor Name for LONSURF
Sponsor	Trials
National Cancer Institute (NCI)	14
Taiho Oncology, Inc.	8
Academic and Community Cancer Research United	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for LONSURF
Sponsor	Trials
Other	63
Industry	32
NIH	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.